Biotech Distilled

Substack ↗ Subscribe

Subscribe Substack ↗ About

Research Areas Modalities Phases Targets Track record Movers The Lead Compound

Home › Targets › R83C

R83C (1 companies · 1 programs)

Companies with an active program directed at R83C.

Beam Therapeutics Inc. BEAM

BEAM-301 — Glycogen Storage Disease Type 1a Phase 1

Track record About Feedback Report a bug Substack ↗

This website is an encyclopedia of clinical-stage biotech companies, refreshed weekly. For informational and educational use only — not investment advice. Always verify against primary sources before making decisions.